Paris, France and Camberley, UK – 28 June 2022 – Novacyt ( EURONEXT GROWTH: ALNOV; AIM: NCYT ), an international specialist in clinical diagnostics, announces the launch of its research-use-only
Paris, France and Camberley, UK – 28 June 2022 – Novacyt ( EURONEXT GROWTH: ALNOV; AIM: NCYT ), an international specialist in clinical diagnostics, announces the launch of its research-use-only
Paris, France and Camberley, UK – 16 June 2022 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces an update on its ongoing dispute with
Paris, France and Camberley, UK – 26 April 2022 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces an update on its ongoing dispute with
Approval of second direct-to-PCR COVID-19 test in the UK under CTDA legislation
Paris, France and Camberley, UK – 17 February 2022 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that the Company’s PROmate ® COVID-19 2G
Full-year revenue and EBITDA in line with expectations
Paris, France and Camberley, UK – 26 November 2021 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that, further to the announcement on 2
Proposed accounting treatment of ongoing DHSC dispute in 2021 interim results
Paris, France and Camberley, UK – 20 August 2021 – Novacyt ( EURONEXT GROWTH: ALNOV; AIM: NCYT ), an international specialist in clinical diagnostics, announces that its Annual General Meeting
Paris, France and Camberley, UK – 18 August 2021 – Novacyt ( EURONEXT GROWTH: ALNOV; AIM: NCYT ), an international specialist in clinical diagnostics, announces a half year update in
Paris, France and Camberley, UK – 5 August 2021 – Novacyt ( EURONEXT GROWTH: ALNOV; AIM: NCYT ), a leading international specialist in clinical diagnostics, announces that it will hold